179 related articles for article (PubMed ID: 20707718)
1. A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
Wong JY; Raubitschek A; Yamauchi D; Williams LE; Wu AM; Yazaki P; Shively JE; Colcher D; Somlo G
Cancer Biother Radiopharm; 2010 Aug; 25(4):387-94. PubMed ID: 20707718
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
5. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Perik PJ; Lub-De Hooge MN; Gietema JA; van der Graaf WT; de Korte MA; Jonkman S; Kosterink JG; van Veldhuisen DJ; Sleijfer DT; Jager PL; de Vries EG
J Clin Oncol; 2006 May; 24(15):2276-82. PubMed ID: 16710024
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
[TBL] [Abstract][Full Text] [Related]
7. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
8. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
9. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
10. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
[TBL] [Abstract][Full Text] [Related]
11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
12. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.
Tang Y; Wang J; Scollard DA; Mondal H; Holloway C; Kahn HJ; Reilly RM
Nucl Med Biol; 2005 Jan; 32(1):51-8. PubMed ID: 15691661
[TBL] [Abstract][Full Text] [Related]
13. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
Pastuskovas CV; Mundo EE; Williams SP; Nayak TK; Ho J; Ulufatu S; Clark S; Ross S; Cheng E; Parsons-Reponte K; Cain G; Van Hoy M; Majidy N; Bheddah S; dela Cruz Chuh J; Kozak KR; Lewin-Koh N; Nauka P; Bumbaca D; Sliwkowski M; Tibbitts J; Theil FP; Fielder PJ; Khawli LA; Boswell CA
Mol Cancer Ther; 2012 Mar; 11(3):752-62. PubMed ID: 22222630
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
16. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
Kramer EL; Liebes L; Wasserheit C; Noz ME; Blank EW; Zabalegui A; Melamed J; Furmanski P; Peterson JA; Ceriani RL
Clin Cancer Res; 1998 Jul; 4(7):1679-88. PubMed ID: 9676842
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
Dijkers EC; Oude Munnink TH; Kosterink JG; Brouwers AH; Jager PL; de Jong JR; van Dongen GA; Schröder CP; Lub-de Hooge MN; de Vries EG
Clin Pharmacol Ther; 2010 May; 87(5):586-92. PubMed ID: 20357763
[TBL] [Abstract][Full Text] [Related]
18. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
19. (111)In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment.
Gaykema SB; de Jong JR; Perik PJ; Brouwers AH; Schröder CP; Oude Munnink TH; Bongaerts AH; de Vries EG; Lub-de Hooge MN
Mol Imaging; 2014; 13(5):. PubMed ID: 24825298
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
